�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a posting presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September fifty-seven, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a post horse session at the ASCO Annual Meeting, Cytokinetics announced interim data from the Phase I portion of its ongoing Phase I/II clinical trial of ispinesib, a novel kinesin spindle protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer the Crab. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from additional patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial ar scheduled to be presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster will be found in the Exhibit Hall at poster board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small atom drugs that may speak areas of significant unmet clinical necessarily. Cytokinetics' cardiovascular disease broadcast is focussed to cardiac myosin, a motor protein essential to cardiac musculus contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. ar performing reefer research focused on identifying and characterizing activators of cardiac myosin as computer backup and follow-on potential drug candidates to CK-1827452. Amgen has obtained an selection for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial involvement rights. Cytokinetics' cancer computer programme is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) ar conducting enquiry and development activities focused on the potential handling of cancer. Cytokinetics is developing 2 novel dose candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally modern or metastatic breast malignant neoplastic disease. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategical alliance by GSK; GSK began a Phase I clinical tribulation with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a electric potential drug candidate directed towards skeletal muscle contractility which may be developed as a electric potential treatment for skeletal musculus weakness associated with neuromuscular diseases or other weather condition. All of these drug candidates and potential drug candidates experience arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a composite biological infrastructure that plays a profound role inside every human cell. Additional information around Cytokinetics can be obtained at hypertext transfer protocol://www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intention or debt instrument to update these innovative statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, merely are non limited to, statements relating to Cytokinetics' research and development programs, including planned presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, electric potential difficulties or delays in the development, testing, regulatory approval or production of Cytokinetics' drug candidates that could slow or keep clinical evolution or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutical efficacy, the U.S. Food and Drug Administration or foreign regulative agencies english hawthorn delay or limit Cytokinetics' or its partners' ability to direct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unforeseen research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change and others may introduce products or alternative therapies for the handling of indications Cytokinetics' do drugs candidates and potential dose candidates may target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its collaborationism agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Cytokinetics
More info
Saturday, 6 September 2008
Sunday, 17 August 2008
Music highlights for Thurs., Aug. 14
Jim McCormick grew up in New Orleans, earned a master's degree in creative writing from the University of New Orleans and is now a professional songster in Nashville. Artists wHO have recorded or performed McCormick's songs include Tim McGraw ("Louisiana"), Luke Bryan (the top 40 bingle "We Rode in Trucks"), Randy Travis ("You Didn't Have a Good Time, " from Travis' new record album), Trisha Yearwood ("Cowboys Are My Weakness") and Amanda Shaw (the title track of her "Pretty Runs Out" CD).
McCormick is featured at this week's early-evening "Ogden After Hours" series at the Ogden Museum of Southern Art. Singer-songwriter Mark Miller, erst of Deadeye Dick, is also on the bill.
Also Thursday, guitarist/vocalist Spencer Bohren diverges from his usual program of
Thursday, 7 August 2008
Francisco
Artist: Francisco
Genre(s):
Other
Discography:
20 Anos Latino CD2
Year:
Tracks: 15
20 Anos Latino CD1
Year:
Tracks: 18
Tuesday, 1 July 2008
Juliana Theory
Artist: Juliana Theory
Genre(s):
Alternative
Rock
Discography:
Love
Year: 2003
Tracks: 6
Emotion Is Dead
Year: 2002
Tracks: 13
The 5 guys wHO receive chosen the somewhat occult nickname of the Juliana Theory to make up their band receive successfully transformed themselves from punk and hard-core kids restricted by the constraints of the emo genre into echt, credible musicians. Their songs display kinetics, skill, and attention to melodious detail that defies their youthful, offbeat, and frequently lyrical affirmative personas.
The Juliana Theory formed in western Pennsylvania in 1997 around vocalist Brett Detar, bassist Chad Alan, guitar player Josh Fiedler, and two other friends. It was in the first place a position stick out for Detar at first due to his commitment as guitarist and major songwriter for metalcore band Zao. Eventually, Detar's poppy position north Korean won over, and he distinct to entrust to the Juliana Theory full-time, amicably exiting Zao.
A split EP with the band Dawson High on Arise Records pronounced the band's recorded debut. Their unrecorded shows were electrical, filled with smile facetiously, bubblegum pop moves -- including the guitarists' predilection for tossing their picks in the air and catching them. Drummer Neil Hebrank and guitar player Josh Kosker were also on base as the Juliana Theory sign a multi-album sell with Seattle-based Tooth & Nail. Their debut uncut, Interpret This Is a Dream, was released on March 23, 1999. It was replete of lackadaisical, impulsive pop songs, but besides hinted at a greater depth that would subsequently be more in full explored.
Simply first base, monumental touring in the album's support was on the plate, with the Juliana Theory share-out stages with many bands and playacting at several national festivals. The band reentered the studio in 2000, number one unleashing a tripartite rent CD with Onelinedrawing and the Gray AM through Onedaysaviour, and next producing the complete, heavily polished, and active Emotion Is Dead album. The Juliana Theory's soph musical composition explored darker depths than their late outings had fey upon, conjuring affectional power ballads and towering rock scorchers through rough-textured layering and incredible harmonies.
Detar began playing tierce guitar more and more in the alive circumstance as the band's fan base increased dramatically. Growing more and more pall of the emo tag and fed up with their bubblegum emo figure and good, the Juliana Theory began maturation yearner hair and written material well more focused compositions. Virtually every major pronounce under the sun became concerned in the group and in 2001, the Juliana Theory signed a recording compress with Epic/Sony. A few dates on the 2001 Warped Tour followed. On October 23 of the like class, the Juliana Theory released vI new songs as the Music from Another Room EP on Tooth & Nail. The songs charted new territory for the quintet, evoking the heroic dynamics of late-'70s prog rockers like Rush, Yes, and Genesis. A round of golf of acting with the similarly minded Movielife and Detar's old match in Zao followed.
The following full-length album, Love, continued this be active away from genre conventions. It showed the isthmus jump into a more mainstream approach without sacrificing its intensity or experimental flourishes. It was too released on Epic, qualification it the official low gear major-label outlet from the isthmus. Epic didn't work out for the Juliana Theory, however, and the set issued a live record album through Tooth & Nail earlier sign language with indie impression Abacus for September 2005's Defaulter Sweetheartbeat. A best-of collection from their years on Tooth and Nail, A Small Noise, appeared in February 2006. That like month, the group officially announced their decision to pick.
Prodigal Sun
Thursday, 26 June 2008
Monday, 16 June 2008
Amy Winehouse: 'I'm The Least Racist Person Going'
Amy Winehouse has apologised for footage that appears to show her singing a 'racist' song.
In the video, which was published in the News of the World, Winehouse and a friend sing a rendition of the song ‘Heads, Shoulders, Knees and Toes’ with the original words replaced.
They repeatedly sing: "Blacks, Pakis, Gooks and Nips, Gooks and Nips.”
Speaking about the footage, Winehouse told photographers outside her North London home yesterday (June 9th): “I don't want to play anything down, but I'm the least racist person going."
The video was reportedly shot by the singer's husband, Blake Fielder-Civil, who can be heard encouraging Winehouse and her friend to sing, reports the Associated Press.
Yesterday it was revealed that Fielder-Civil had pleaded guilty to assaulting a man and then trying to cover it up.
If found guilty of the incident, which took place outside a pub in London in 2006, Winehouse's husband could face a maximum of five years in jail.
Winehouse emerged briefly yesterday to sign autographs for fans. You can see the pictures below...
See Also
Friday, 6 June 2008
Kenny Neal
Artist: Kenny Neal
Genre(s):
Blues
Other
Discography:
Homesick for the Road
Year: 1999
Tracks: 12
Hoodoo Moon
Year: 1994
Tracks: 12
Bayou Blood
Year: 1992
Tracks: 14
Walking on Fire
Year: 1991
Tracks: 12
Devil Child
Year: 1989
Tracks: 11
Big News from Baton Rouge!!
Year: 1988
Tracks: 11
The next of Baton Rouge swampland blues lies forthright in multi-instrumentalist Kenny Neal's up to custody -- the second-generation southern Louisiana bluesman is entirely aware of the region's venerable megrims tradition and imaginative enough to steer it in fresh directions, as his albums for Alligator confirm. His dada, harper Raful Neal, was a Baton Rouge blues mainstay whose pals included Buddy Guy and Slim Harpo (the latter handed three-year-old horse Kenny an old harp one day as a toy, and that was it). At age 13, Neal was playing in his father's band, and he picked up a bass at 17 for Buddy Guy. In 1987, Neal cut off his debut LP for Florida producer Bob Greenlee -- a stunningly updated swampland banquet initially marketed on King Snake Records as Bio on the Bayou. Alligator picked it up the following year, retitled it Vainglorious News from Baton Rouge!!, and offspring Neal was on his way. Neal's sizzling guitar work, inflexible harp, and shingly, aged-beyond-his-years vocals hold served him well ever since. Among his legion albums ar Devil Child (1989), Bayou Blood (1992), Hoodoo Moon (1994), Blues Fallin' Down Like Rain (1998), What You Got (2000), One Step Closer (2001), Easy Meeting (2003), Double Take (2004), and A Trubute to Slim Harpo and Raful Neal (2005).
Linkin Park
Subscribe to:
Posts (Atom)